162 related articles for article (PubMed ID: 35115484)
1. Intracellular CYTL1, a novel tumor suppressor, stabilizes NDUFV1 to inhibit metabolic reprogramming in breast cancer.
Xue W; Li X; Li W; Wang Y; Jiang C; Zhou L; Gao J; Yu Y; Shen Y; Xu Q
Signal Transduct Target Ther; 2022 Feb; 7(1):35. PubMed ID: 35115484
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer cells have an increased ferroptosis risk induced by system x
Xue W; Yu Y; Yao Y; Zhou L; Huang Y; Wang Y; Chen Z; Wang L; Li X; Wang X; Du R; Shen Y; Xu Q
Redox Biol; 2024 Apr; 70():103034. PubMed ID: 38211443
[TBL] [Abstract][Full Text] [Related]
3. CYTL1 Promotes the Activation of Neutrophils in a Sepsis Model.
Xue H; Li S; Zhao X; Guo F; Jiang L; Wang Y; Zhu F
Inflammation; 2020 Feb; 43(1):274-285. PubMed ID: 31823178
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and biophysical characterization of cytokine-like protein 1 (CYTL1).
Tomczak A; Singh K; Gittis AG; Lee J; Garboczi DN; Murphy PM
Cytokine; 2017 Aug; 96():238-246. PubMed ID: 28478073
[TBL] [Abstract][Full Text] [Related]
5. Protein Cytl1: its role in chondrogenesis, cartilage homeostasis, and disease.
Zhu S; Kuek V; Bennett S; Xu H; Rosen V; Xu J
Cell Mol Life Sci; 2019 Sep; 76(18):3515-3523. PubMed ID: 31089746
[TBL] [Abstract][Full Text] [Related]
6. Cytokine-Like 1 Is a Novel Proangiogenic Factor Secreted by and Mediating Functions of Endothelial Progenitor Cells.
Schneller D; Hofer-Warbinek R; Sturtzel C; Lipnik K; Gencelli B; Seltenhammer M; Wen M; Testori J; Bilban M; Borowski A; Windwarder M; Kapel SS; Besemfelder E; Cejka P; Habertheuer A; Schlechta B; Majdic O; Altmann F; Kocher A; Augustin HG; Luttmann W; Hofer E
Circ Res; 2019 Jan; 124(2):243-255. PubMed ID: 30582450
[TBL] [Abstract][Full Text] [Related]
7. Metabolic reprogramming of cancer-associated fibroblasts by TGF-β drives tumor growth: connecting TGF-β signaling with "Warburg-like" cancer metabolism and L-lactate production.
Guido C; Whitaker-Menezes D; Capparelli C; Balliet R; Lin Z; Pestell RG; Howell A; Aquila S; Andò S; Martinez-Outschoorn U; Sotgia F; Lisanti MP
Cell Cycle; 2012 Aug; 11(16):3019-35. PubMed ID: 22874531
[TBL] [Abstract][Full Text] [Related]
8. The involvement of cytokine-like 1 (Cytl1) in chondrogenesis and cartilage metabolism.
Zhu W; Yang X; Liu S; Wang M; Ye S; Luo H; Cui S
Biochem Biophys Res Commun; 2020 Aug; 529(3):608-614. PubMed ID: 32736681
[TBL] [Abstract][Full Text] [Related]
9. p53/Lactate dehydrogenase A axis negatively regulates aerobic glycolysis and tumor progression in breast cancer expressing wild-type p53.
Zhou Y; Niu W; Luo Y; Li H; Xie Y; Wang H; Liu Y; Fan S; Li Z; Xiong W; Li X; Ren C; Tan M; Li G; Zhou M
Cancer Sci; 2019 Mar; 110(3):939-949. PubMed ID: 30618169
[TBL] [Abstract][Full Text] [Related]
10. Cytokine-like 1 Chemoattracts Monocytes/Macrophages via CCR2.
Wang X; Li T; Wang W; Yuan W; Liu H; Cheng Y; Wang P; Zhang Y; Han W
J Immunol; 2016 May; 196(10):4090-9. PubMed ID: 27084102
[TBL] [Abstract][Full Text] [Related]
11. The FoxQ1 transcription factor is a novel regulator of electron transport chain complex I subunits in human breast cancer cells.
Kim SH; Singh SV
Mol Carcinog; 2022 Mar; 61(3):372-381. PubMed ID: 34939230
[TBL] [Abstract][Full Text] [Related]
12. RNA-binding protein RNPC1: acting as a tumor suppressor in breast cancer.
Xue JQ; Xia TS; Liang XQ; Zhou W; Cheng L; Shi L; Wang Y; Ding Q
BMC Cancer; 2014 May; 14():322. PubMed ID: 24884756
[TBL] [Abstract][Full Text] [Related]
13. CYTL1 inhibits tumor metastasis with decreasing STAT3 phosphorylation.
Wang X; Li T; Cheng Y; Wang P; Yuan W; Liu Q; Yang F; Liu Q; Ma D; Ding S; Wang J; Han W
Oncoimmunology; 2019; 8(5):e1577126. PubMed ID: 31069137
[TBL] [Abstract][Full Text] [Related]
14. CYTL1 regulates bone homeostasis in mice by modulating osteogenesis of mesenchymal stem cells and osteoclastogenesis of bone marrow-derived macrophages.
Shin Y; Won Y; Yang JI; Chun JS
Cell Death Dis; 2019 Jan; 10(2):47. PubMed ID: 30718470
[TBL] [Abstract][Full Text] [Related]
15. Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.
Zhao K; Zhou Y; Qiao C; Ni T; Li Z; Wang X; Guo Q; Lu N; Wei L
J Hematol Oncol; 2015 Apr; 8():41. PubMed ID: 25902914
[TBL] [Abstract][Full Text] [Related]
16. Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP.
Shen L; O'Shea JM; Kaadige MR; Cunha S; Wilde BR; Cohen AL; Welm AL; Ayer DE
Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5425-30. PubMed ID: 25870263
[TBL] [Abstract][Full Text] [Related]
17. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades.
Lu Y; Yu Q; Liu JH; Zhang J; Wang H; Koul D; McMurray JS; Fang X; Yung WK; Siminovitch KA; Mills GB
J Biol Chem; 2003 Oct; 278(41):40057-66. PubMed ID: 12869565
[TBL] [Abstract][Full Text] [Related]
18. The NQO1/PKLR axis promotes lymph node metastasis and breast cancer progression by modulating glycolytic reprogramming.
Yang Y; Zhu G; Dong B; Piao J; Chen L; Lin Z
Cancer Lett; 2019 Jul; 453():170-183. PubMed ID: 30954648
[TBL] [Abstract][Full Text] [Related]
19. ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer.
Hu R; Peng G; Dai H; Breuer EK; Stemke-Hale K; Li K; Gonzalez-Angulo AM; Mills GB; Lin SY
Cancer Res; 2011 Oct; 71(20):6524-34. PubMed ID: 21852383
[TBL] [Abstract][Full Text] [Related]
20. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression.
Vaupel P; Schmidberger H; Mayer A
Int J Radiat Biol; 2019 Jul; 95(7):912-919. PubMed ID: 30822194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
